Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.
Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated approval from FDA. We anticipate rapid launch and uptake of EXONDYS 51, with peak US sales of ~ $425M as a floor; we see upside as boys grow older and remain on drug. We have lowered our discount rate for the program, driving our price target increase. We note Sarepta has received a priority review voucher (PRV) with approval, which we value for now at $300M ($5/share); in our view, this voucher can mitigate the need for future dilutive financing. We continue to recommend shares of Sarepta at these levels ahead of launch."
The analyst said Sarepta will launch EXONDYS 51 right away at an average net price of $300,000, lower than the firm's expected net price of $425,000; however, it is weight-based and we expect increased net pricing with time.
Shares of Sarepta Therapeutic closed at $48.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Pepsi (PEP) to $122; Reiterates Buy
- BMO Capital Reiterates Outperform on Pepsi (PEP) Following Solid 3Q
- Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!